We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+57.31%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$253M
AUM Growth
+$105M
(+72%)
Cap. Flow
+$69.1M
Cap. Flow
% of AUM
27.37%
Top 10 Holdings %
Top 10 Hldgs %
50.9%
Holding
95
New
29
Increased
11
Reduced
6
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$8.24M |
| 2 |
Biohaven
BHVN
|
+$6.93M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$5.72M |
| 4 |
Larimar Therapeutics
LRMR
|
+$5.42M |
| 5 |
HELP
Cybin Inc
HELP
|
+$5.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
+$9.75M |
| 2 |
ATXS
Astria Therapeutics
ATXS
|
+$7.32M |
| 3 |
Immunovant
IMVT
|
+$3.37M |
| 4 |
Oric Pharmaceuticals
ORIC
|
+$3.22M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$2.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.9% |
| 2 | Consumer Discretionary | 1.37% |
| 3 | Industrials | 0.06% |
| 4 | Communication Services | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vera Therapeutics
VERA
$2.39B
| $30.6M | 12.12% |
710,000
+95,000
| +15% | +$3.39M |
|
2
Xenon Pharmaceuticals
XENE
$6.28B
| $15M | 5.93% |
348,000
+57,465
| +20% | +$2.64M |
|
3
PUT
Viking Therapeutics
VKTX
$3.93B
| $14.4M | 5.69% |
+175,300
| New | +$7.8M |
|
|
DENT
4
CALL
DELISTED
AdvisorShares Dent Tactical ETF
DENT
| $11.3M | 4.46% |
+1,125,000
| New | +$11.3M |
|
5
Axsome Therapeutics
AXSM
$12.1B
| $11M | 4.36% |
138,000
| – | – |
|
6
ADMA Biologics
ADMA
$2.04B
| $10.2M | 4.02% |
1,540,000
+445,000
| +41% | +$2.43M |
|
|
ALIM
7
DELISTED
Alimera Sciences
ALIM
| $9.95M | 3.94% |
2,550,000
-110,000
| -4% | -$419K |
|
|
AVDL
8
DELISTED
Avadel Pharmaceuticals
AVDL
| $9.34M | 3.7% |
+553,057
| New | +$8.24M |
|
9
Xtant Medical Holdings
XTNT
$59.7M
| $8.95M | 3.54% |
7,647,873
-379,720
| -5% | -$416K |
|
|
CPRX
10
DELISTED
Catalyst Pharmaceutical
CPRX
| $7.97M | 3.15% |
500,000
+115,000
| +30% | +$1.73M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.82M | 3.09% |
113,000
+42,000
| +59% | +$2.89M |
|
|
12
Biohaven
BHVN
$2.07B
| $7.66M | 3.03% |
+140,000
| New | +$6.93M |
|
|
13
Viking Therapeutics
VKTX
$3.93B
| $6.97M | 2.76% |
+85,000
| New | +$3.78M |
|
14
Olema Pharmaceuticals
OLMA
$1.01B
| $6.85M | 2.71% |
605,000
+191,393
| +46% | +$2.47M |
|
15
Savara
SVRA
$1.09B
| $6.65M | 2.63% |
1,335,000
+2,000
| +0.2% | +$9.66K |
|
|
SLNO
16
DELISTED
Soleno Therapeutics
SLNO
| $6.54M | 2.59% |
152,909
+48,000
| +46% | +$2.17M |
|
|
HELP
17
Cybin Inc
HELP
$471M
| $5.77M | 2.28% |
+367,197
| New | +$5.3M |
|
|
18
Oric Pharmaceuticals
ORIC
$1.23B
| $5.57M | 2.2% |
405,000
-271,000
| -40% | -$3.22M |
|
|
19
Larimar Therapeutics
LRMR
$398M
| $5.28M | 2.09% |
+695,000
| New | +$5.42M |
|
|
20
Mirum Pharmaceuticals
MIRM
$6.84B
| $5.22M | 2.07% |
+208,000
| New | +$5.72M |
|
21
Neurogene
NGNE
$663M
| $5.09M | 2.01% |
100,000
+33,019
| +49% | +$1.1M |
|
22
Praxis Precision Medicines
PRAX
$8.25B
| $4.77M | 1.89% |
+78,100
| New | +$3.5M |
|
23
Achieve Life Sciences
ACHV
$634M
| $3.8M | 1.5% |
+835,470
| New | +$3.71M |
|
24
Ascendis Pharma A/S
ASND
$16.7B
| $3.78M | 1.5% |
25,000
| – | – |
|
|
LBPH
25
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $3.67M | 1.45% |
+170,000
| New | +$3.71M |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q1 2024 Portfolio in Review
As of Q1 2024, Altium Capital Management held 95 positions worth $253M, up 72% from $147M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Altium Capital Management deployed $69.1M of net new capital in Q1 2024, opening 29 new positions and adding to 11 existing holdings. Its largest new stake was Avadel Pharmaceuticals: 553,057 shares worth $9.34M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Astria Therapeutics, an estimated $7.32M trimmed.
- Altium Capital Management's largest Q1 2024 buy was Avadel Pharmaceuticals: 553,057 shares worth $9.34M.
- Altium Capital Management added most to Vera Therapeutics in Q1 2024, an estimated $3.39M increase.
- Altium Capital Management's biggest Q1 2024 reduction was Astria Therapeutics, cutting an estimated $7.32M.
- Altium Capital Management fully exited Alpha Architect 1-3 Month Box ETF in Q1 2024, selling an estimated $9.75M.
- Altium Capital Management's ten largest holdings make up 51% of its $253M portfolio in Q1 2024.
- Altium Capital Management opened 29 new positions and closed 23 in Q1 2024.
- Altium Capital Management's portfolio value rose 72% quarter-over-quarter to $253M.
Based on Altium Capital Management's 13F filing for Q1 2024, filed 15 May 2024.